Newsletter Tool

PM Tracker

Today’s Big News

Feb 10, 2025

UPDATE: 22 states sue NIH over biomedical research grant cap designed to save $4B annually

Incyte's JAK cream Opzelura picks up steam as company works to revive Jakafi XR dreams

Boehringer widens fibrosis drug’s approval path after boosting lung function in 2nd phase 3 trial

Federal judge says Trump admin is violating order to halt funding freezes, NIH cuts

Eli Lilly inks duo of deals, teaming with AdvanCell, OliX to push deeper into radiopharma, MASH

Bristol Myers angles Breyanzi for another blood cancer as it works to close Gilead's CAR-T lead

Pliant pauses phase 2 lung fibrosis trial on advice of safety committee

FDA amplifies BD atherectomy safety alert following 4 deaths

Featured

UPDATE: 22 states sue NIH over biomedical research grant cap designed to save $4B annually

By Gabrielle Masson

A new initiative rolled out under President Donald Trump’s administration is cutting billions from grants for "indirect costs" tied to biomedical research, such as facilities, equipment and administrative expenses.

Incyte's JAK cream Opzelura picks up steam as company works to revive Jakafi XR dreams

By Zoey Becker

With Incyte's bread-and-butter Jakafi approaches a 2028 patent cliff, its topical counterpart Opzelura is gaining momentum as several expansion opportunities take shape.

Boehringer widens fibrosis drug’s approval path after boosting lung function in 2nd phase 3 trial

By James Waldron

Boehringer Ingelheim has cemented the potential of its idiopathic pulmonary fibrosis (IPF) drug with a second phase 3 win in a related lung disease leading the drugmaker to expand the indications it will seek FDA approval for.

Federal judge says Trump admin is violating order to halt funding freezes

By Dave Muoio,Noah Tong

The Trump administration is violating a temporary restraining order by continuing to improperly freeze federal funds—including those related to National Institutes of Health and other agencies, per a Monday order.

Eli Lilly inks duo of deals, teaming with AdvanCell, OliX to push deeper into radiopharma, MASH

By Nick Paul Taylor

Eli Lilly has begun the week with a bang. Early Monday morning, AdvanCell and OliX Pharmaceuticals put out news that the Big Pharma is coughing up cash to work with them on radiopharmaceuticals and metabolic-associated steatohepatitis, respectively.

Bristol Myers angles Breyanzi for another blood cancer as it works to close Gilead's CAR-T lead

By Angus Liu

With another trial win, Bristol Myers Squibb is touting Breyanzi as the CD19-directed CAR-T therapy with positive readouts in the most cancer types.

Pliant pauses phase 2 lung fibrosis trial on advice of safety committee

By James Waldron

Pliant Therapeutics has hit the breaks on a midstage trial of its lead liver disease drug on the advice of its safety committee.

FDA amplifies BD atherectomy safety alert following 4 deaths

By Conor Hale

According to the agency, BD has reported 30 serious injuries and four deaths linked to fractures or breaks within its Rotarex atherectomy systems.

AbbVie scores FDA nod for Pfizer-partnered antibiotic Emblaveo

By Kevin Dunleavy

Ten months after Pfizer scored approval in Europe for Emblaveo to treat complicated intra-abdominal infections, AbbVie has done the same in the U.S., winning an FDA nod for Emblaveo for the same type of Gram-negative infections.

Globus Medical to buy neurostim developer Nevro for $250M

By Conor Hale

With Globus paying $5.85 for each of Nevro’s outstanding shares, that amounts to a 27% premium over a 90-day weighted average.

Merck KGaA sets its sights on acquisition of Ogsiveo-maker SpringWorks: Reuters

By Fraiser Kansteiner

Merck KGaA is said to be in advanced talks to acquire cancer and are disease specialist SpringWorks, which has a market value of around $3 billion, Reuters reported Monday, citing people close to the matter. Should everything go to plan, the deal could be inked in the coming weeks.

Fierce podcasts

Don’t miss an episode

Looking ahead at the most anticipated drug launches of 2025

This week on "The Top Line," we dig into the 10 biggest potential drug launches of 2025, predicted to rake in a combined $29 billion in annual sales by the end of the decade.